TMDI VS BIOC Stock Comparison

Performance

TMDI
10/100

TMDI returned -73.08% in the last 12 months. Based on the other stocks in it's sector with an average return of -23.10%, it's performance is below average giving it a grade of 10 of 100.

BIOC
10/100

BIOC returned -98.16% in the last 12 months. Based on SPY's performance of -16.96%, its performance is below average giving it a score of 10 of 100.

Sentiment

TMDI
65/100

TMDI had a bullish sentiment score of 64.63% across Twitter and StockTwits over the last 12 months. It had an average of 17.43 posts, 15.89 comments, and 57.00 likes per day.

BIOC

"Sentiment" not found for BIOC

Technicals

TMDI
14/100

TMDI receieves a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

BIOC
14/100

BIOC receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

TMDI
16/100

TMDI has missed earnings 3 times in the last 20 quarters.

BIOC
10/100

BIOC has missed earnings 9 times in the last 20 quarters.

Volatility

TMDI
55/100

TMDI has had a higher than average amount of volatility over the last 12 months giving it a grade of 54 of 100.

BIOC
50/100

BIOC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

Analyst Price Targets

TMDI

"Analyst Price Targets" not found for TMDI

BIOC
75/100

3 analysts offer 12-month price targets for BIOC. Together, they have an average target of 0, the most optimistic target put BIOC at 0 within 12-months and the most pessimistic has BIOC at 0.

Profit

TMDI

"Profit" not found for TMDI

BIOC
19/100

Out of the last 20 quarters, BIOC has had 3 profitable quarters and has increased their profits year over year on 3 of them.

All score calculations are broken down here to help you make more informed investing decisions

Titan Medical Inc. Ordinary Shares Summary

Nasdaq / TMDI

Healthcare

Medical Devices

Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during surgical procedures. The company is headquartered in Toronto, Canada.

Biocept, Inc. Summary

Nasdaq / BIOC

Healthcare

Diagnostics & Research

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Power up your portfolio